coming down to Aroa and Polynovo; Avita seems out of the race for bow, page-19

@dogzrule

Aroa is absolutely a competitor. But, as a biologic, it will suffer from the same limitations as integra when it comes to its use as a dermal scaffold for reconstruction (Myriad). The literature for this product, posted on their website, is still quite scarce, and it's funded by Aroa.

For chronic wounds, this appears to be where Aroa has been focussed historically (Endoform). They have been around for much longer than PNV, and we will be competing when we begin pushing into the massive chronic wound market. Looking at the literature on their website, there's a couple case studies from last year independently published but the majority are, again, sponsored by Aroa.

Not of that is bad, mind you, but contrast that to the independent groups publishing their results with BTM.

None of us are denying we have competition. But to create a thread specifically mentioning AVH (which indicates you don't really grasp what you're talking about), especially after creating that click bait nonsense thread previously, and going on the offensive attacking others here for being frustrated is a bold move.

I found it funny you called us a bunch of "Numpties" on your recent post on ARX as well. If you want to have an actual discussion, there are many less offensive ways to go about it.